Skip to main content
. 2023 Dec 1;11(1):167–176. doi: 10.1007/s40801-023-00400-3

Fig. 2.

Fig. 2

Proportion of patients with coexistent triple disease prescribed with various monotherapy and combination therapy. ACEi angiotensin converting enzyme inhibitors, AGI alpha-glucosidase inhibitors, ARB angiotensin receptor blockers, CCB calcium channel blockers, T2DM type 2 diabetes mellitus, DPP4 dipeptidyl-peptidase 4, GLP1 glucagon-like peptide-1, PPAR peroxisome proliferator-activated receptor, SGLT2 sodium–glucose cotransporter-2, TZD thiazolidinediones